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Abstract
Patients: Soft tissue sarcomas are uncommon malignancies with few therapeutic options for recurrent or metastatic disease.
Dolastatin-10 (Dol-10) is a pentapeptide anti-microtubule agent that binds to tubulin sites distinct from vinca alkaloids.
Based on the novel mechanism of action, limited activity of other anti-microtubular agents, and anti-neoplastic activity in
pre-clinical screening of Dol-10, this multi-institutional phase II study was conducted to determine the objective response
rate of Dol-10 in recurrent or metastatic soft tissue sarcomas that had not been treated with chemotherapy outside of the
adjuvant setting.
Methods: Dol-10 was given intravenously at a dose of 400 mg/m
2 and repeated every 21 days. Toxicities were assessed using
the Common Toxicity Criteria (version 2.0). Radiographic studies and tumor measurements were repeated every two cycles
to assess response [Miller AB, et al. Cancer 1981; 47(1): 207].
Results: Dol-10 was associated with hematological toxicity and with some vascular toxicities. There was no significant
gastrointestinal, hepatic or renal toxicity. There was one death on study due to respiratory failure. There were no objective
responses in 12 patients treated with Dol-10.
Discussion: Based on this phase II trial, further study of Dol-10 on this schedule is not recommended in advanced or
metastatic soft tissue sarcomas.
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Abbreviation
Dol-10 dolastatin-10
STS soft tissue sarcomas
ip intraperitoneal
DAB diaminobenzidene
GIST gastrointestinal stromal tumor
Introduction
Soft tissue sarcomas (STS) are an uncommon tumor
with poor survival. Some patients with metastatic or
locally recurrent disease require chemotherapy and
radiation therapy for palliation. In the metastatic
disease setting, chemotherapy regimens have an
overall response rate of 30–40%, with only rare
prolonged complete remissions. Clinical trials of
doxorubicin as a single agent or in combined
modality therapies have demonstrated response
rates in the range of 15–34%, although without
evidence for a survival benefit.
2–5 The anti-tumor
activity of other chemotherapeutic agents,
6–10 high
dose therapy with transplantation,
11,12 and immu-
nological therapies
13–16 have not been encouraging.
Consequently, there is an urgent need to identify
new active agents for this disease. Given the limited
activity of agents available for the treatment of soft
tissue sarcoma, a trial testing a new agent as first line
therapy was considered acceptable.
Dolastatins are naturally occurring pentapeptides
isolated from the East Indian Ocean Sea hare
Dolabella auricularia.
17 Extracts from the sea hare
were found to have anti-tumor activity in the NCI
intraperitoneal (ip) P388 leukemia model. Dol-10,
which is now synthesized,
18 has a linear peptide
structure of four amino acids linked to a complex
primary amine. Three of its amino acids (dolavaline,
dolaisoleucine, and dolaproline) and its terminal
amine (dolaphenine) are unique to the mollusk from
which it was isolated.
19 Dol-10 is a potent antimotic
agent, similar to the vinca alkaloids and taxanes.
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The anti-microtubule agents vindesine, paclitaxel
and docetaxel have been investigated in STS with
response rates up to 19% in phase II studies.
21–23
Thus, in STS it is reasonable to evaluate novel agents
in this class that bind to unique sites on tubulin. The
purpose of this multi-institutional phase II study was
to evaluate the toxicity and efficacy of Dol-10 in
patients with recurrent or metastatic disease, not
previously treated with chemotherapy outside of the
adjuvant setting.
Patients
This multi-institutional study enrolled patients at
Fox Chase Cancer Center, Mayo Clinic, Ohio State
University, and University of Colorado between
April 1999 and February 2000. Eligibility criteria
included: written informed consent, histologically
confirmed soft tissue sarcoma that was recurrent or
metastatic, measurable disease, no prior chemother-
apy except adjuvant chemotherapy, no prior radia-
tion therapy unless there was progressive measurable
disease outside of the radiation port, an Eastern
Cooperative Oncology Group performance status
of 0 or 1, and adequate hepatic, renal, and bone
marrow function. Women of child-bearing potential
had to have a negative pregnancy test within 72h
prior to the first cycle. Patients were required to use
contraception during study participation.
Exclusion criteria included: a diagnosis of rhabdo-
myosarcoma, Ewing’s sarcoma, chondrosarcoma,
osteogenic sarcoma, mesothelioma, or Kaposi’s
sarcoma; also a history of brain metastases, uncon-
trolled infection, breast-feeding female patients or a
history of malignancy other than basal or squamous
cell carcinomas of the skin, or in situ carcinoma of the
cervix, diagnosed within the past 5 years.
Materials and Methods
Protocol procedures
Dol-10 was supplied by the Cancer Therapeutics
Evaluation Program of the National Cancer
Institute. Patients received Dol-10, 400 mg/m
2
intravenously over 10min every 21 days. Complete
blood counts were obtained weekly and a chemistry
panel every 3 weeks. Toxicities were assessed using
the Common Toxicity Criteria (version 2.0). Tumor
measurements were repeated every two cycles to
assess response using standard criteria.
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Dose modification criteria
Grade 4 hematological toxicity at any time resulted
in a 25% dose reduction. If tolerated without a
further grade 3–4 toxicity, one dose escalation of
12.5% was allowed. Patients with grade 3–4 hema-
tological toxicity on day 21 were delayed 7 days.
If not recovered after 7 days, patients were taken off
study. Any other non-hematological or neurological
grade 3–4 toxicity required a 25% dose reduction,
with the exception of nausea, vomiting, and diarrhea,
unless inadequately controlled by optimal supportive
therapies. Patients who tolerated reduced doses
were allowed a 12.5% (for prior grade 4) and 25%
(for prior grade 3) dose escalation, whereas those
whose toxicity did not improve to less than a grade
3 were taken off study. Patients who received at least
2 consecutive cycles of 400mgm/m
2 without grade
3–4 toxicities were eligible for a dose escalation to
450mgm/m
2.
Statistical analysis
This phase II study was designed to assess the
frequency and extent of anti-tumor activity of Dol-10
in a population of patients with recurrent or
metastatic soft tissue sarcoma. The primary endpoint
was overall objective response proportion (complete
and partial response). At the time this trial was
designed, a proportion of patients with favorable
response less than 5.0% was deemed of no interest.
The new treatment would be of interest if the
proportion of patients (p) with tumor response was
at least 20.0%. Thirty-seven patients would be
needed to test the null hypothesis (P 0.050) against
the alternative hypothesis (p 0.200) at the 3.2%
level of significance and with 84.8% power. An early
stopping rule for futility was applied such that if
no patients with CR or PR were observed when
12 patients were accrued, then the null hypothesis
would be accepted and the trial terminated. The
probability of early stopping under the null hypoth-
esis was 0.54, and under the alternative was 0.07. If
the trial progressed until 37 patients were evaluated
and five or more patients with favorable response
were observed, then the null hypothesis would be
rejected.
Results
Patient characteristics
A total of twelve patients were enrolled on the study
from April 1999 to February 2000 at the four
centers. Patient characteristics are summarized
in Table 1. The most common diagnosis was
leiomyosarcoma. Pretreatment was minimal with
only one patient treated with chemotherapy in the
adjuvant setting. Four patients had prior adjuvant
radiation therapy and one had palliative therapy.
A total of 26 cycles of treatment were given.
One patient received five cycles, 10 patients received
2 cycles, and one patient received only one cycle
of therapy.
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Table 2 describes the toxicities observed during all
26 cycles of therapy. The majority of the observed
adverse events were grade 1 or 2 (71%). Anemia was
the most frequent hematological toxicity. Grade 3
anemia was noted in a patient with leiomyosarcoma
and a history of intraperitoneal bleeding who
presented on cycle 1, day 2 with abdominal pain
and hypotension. CT scan revealed hemoperito-
neum. After cycle 2 with a 25% dose reduction, the
patient had recurrent hemoperitoneum with bleeding
from tumor confirmed at exploratory laporotamy.
The recurrent episodes in a tumor known for
bleeding implicated the underlying disease rather
than Dol-10 as the likely cause. The second patient
with grade 3 anemia, also with leiomyosarcoma,
began treatment with grade one anemia and had a
progressive decline in hemoglobin without evidence
of bleeding.
There were three episodes of grade 3 leukopenia
associated with concurrent neutropenia. Nadirs were
seen on day 21, requiring a week delay. Only one
patient developed an Eschericiae coli urinary tract
infection in association with grade 4 neutropenia.
Alterations in liver function tests were all associated
with progressive metastatic liver disease at the initial
response evaluation.
Two patients experienced grade 3 and 4 cardio-
pulmonary toxicities, with one resulting in death.
Patient 2 had a history of spindle cell sarcoma with
a past medical history significant for hypertension.
On day 1 she was noted to be hypertensive having
not taken her blood pressure medications. Her blood
pressure increased after the Dol-10 infusion, but
improved with anti-hypertensive therapy. On day 2
the patient had persistent hypertension, and her
anti-hypertensive medications were increased. She
stopped taking her anti-hypertensives again on day 4
and was hospitalized on day 8 with hypertension
and congestive heart failure. She expired on day
10 of respiratory failure. As hypertension has been
reported as a potential side effect of dolastatins,
this was considered to be a possible drug toxicity.
The second patient had tachycardia secondary to
hemoperitoneum and anemia as described above.
Clinical response
Of the 12 patients entered on study, 11 received
at least two cycles of therapy. Ten patients were
removed from study after the first two cycles of
therapy with progressive disease. Patient 12 received
five cycles of therapy. Radiographically the patient
had stable disease but had increasing tumor related
pain and was removed from study to receive
palliative radiation therapy.
Discussion
STS are a heterogeneous group of tumors with
few effective therapies. This study evaluated a new
Table 2. Summary of toxicity using the Common Toxicity
Criteria version 2.0: worst grade for all cycles of treatment
Toxicity Grade and No. of patients with toxicity
12 34
White blood cell 2 1 3 0
Neutrophil count 0 0 3 1
Platelet count 2 0 0 0
Anemia 10 1 2 0
Bleeding 0 0 1 1
Abdominal pain 1 1 1 0
Nausea 2 2 0 0
Vomiting 0 3 0 0
Liver function 4 1 0 0
Hyponatremia 2 0 1 0
Hypoalbuminemia 5 0 0 0
Hypokalemia 2 0 1 0
Edema 0 0 2 0
Dizziness 1 0 2 0
Hypotension 1 0 1 0
Hypertension 1 0 1 0
Arrhythmia 2 0 2 0
Chest Pain 1 1 0 0
SOB/hypoxia 0 1 1 2
 
Fatigue/weakness 12 2 2 1
Headache 2 0 1 0
Night sweats 2 1 0 0
Skin changes 2 0 0 0
IV site reactions 1 3 0 0
Sacral pain 0 2 0 0
Toxicity observed in all cycles of Dol-10 using the Common
Toxicity Criteria, version 2.0.
 One event resulted in death within 30 days of drug and is
classified as a death on study.
Table 1. Patient characteristics
N (%)
Age
Range 40–74
Median 57
Sex
Male 4 (33%)
Female 8 (67%)
Performance status
PS¼0 5 (42%)
PS¼1 7 (58%)
Histology
Leiomyosarcoma 7 (58%)
 
Synovial sarcoma 2 (17%)
Malignant fibrous histiocytoma 1 (8%)
Angiosarcoma 1 (8%)
Spindle Cell 1 (8%)
Prior therapy
Surgery 12 (100%)
Radiation therapy 4 (33%)
Adjuvant chemotherapy 1 (8%)
 Following trial participation, one patient was found to have KIT
expression and was reclassified as having a gastrointestinal stromal
tumor.
Phase II trial of dolastatin-10 in soft tissue sarcomas 109anti-microtubular agent in patients with recurrent
or metastatic disease who were chemotherapy naı ¨ve
with the exception of adjuvant therapy. Because
there were no objective responses in 12 evaluable
patients, the study was closed to further accrual.
The heterogeneity of histological STS subtypes
may have obscured activity in one histological subset
as too few patients of any one subtype were treated.
In preclinical studies, Dol-10 was active against
leukemia,
24 and non-small cell lung cancer cell
lines.
25 Phase I and phase II studies utilizing Dol-
10 did not demonstrate any objective responses in a
variety of solid tumors.
26 A trial in acute leukemia
demonstrated decreases in peripheral blast counts,
and one patient had a partial response.
27 The
toxicities observed in our patients were consistent
with those observed in phase I studies of Dol-10. The
hypertension noted in this study was described
preclinically in dog studies and in one prior phase I
trial.
28 Another compound derived from Dolabela
auricularia, Dolastatin-15, had arterial hypertension
and myocardial infarction as the dose-limiting
toxicities.
Among the possibilities for the lack of efficacy of
Dol-10 is inherent in phase II trials of soft tissue
sarcomas due to the multiple histologies accrued to
studies. In addition, review of patient histories
suggests that four of the seven patients with
leiomyosarcoma likely had gastrointestinal stromal
tumor (GIST), with one confirmed by KIT immu-
nostaining. This histology has been shown to be
refractory to chemotherapy.
29 These data were not
available at the time of the development of this study.
If our study contained four GIST patients out of the
12 patients, this may in part account for the lack of
response seen. Another potential etiology for the
inactivity is multidrug resistance, as STS are known
to express high levels of MDR1.
30 Murine and
human leukemia cell lines that express MDR1 have
been shown to be resistant to Dol-10.
31 In addition,
a clinical trial in acute leukemias in which patients
were noted to have a decline in their peripheral
blast count, suggested a correlation between Dol-10
efficacy and MDR1 expression.
27
In summary, as gauged by standard response
criteria, Dol-10 as first-line therapy was inactive in
12 patients with recurrent or metastatic soft tissue
sarcoma. The lack of efficacy is particularly striking
in this patient population with minimal pre-treat-
ment. Recent data from the European Organization
for Research and Treatment of Cancer Soft Tissue
and Bone Sarcoma Group has identified therapy with
doxorubicin-based regimens as a factor associated
with improved long-term survival in patients with
metastatic soft tissue sarcoma.
32 Future phase II
studies should consider the appropriateness of
testing new agents in patients that have not
previously been treated with doxorubicin.
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